Abstract
Nasal polyposis is the end result of a variety of pathologic processes. The aims of treatment are to relieve nasal blockage, restore olfaction, and improve sinus drainage. Treating any accompanying rhinitis is also an aim, which requires that medical treatment be given to all patients with an inflammatory problem. Most forms of nasal polyp recur after treatment, whether medical or surgical. There are few direct comparisons of medical and surgical treatment in the literature. Those that exist suggest that most patients should be treated medically, with surgery reserved for patients who respond poorly. Large prospective randomized trials of surgical versus medical therapy are needed in groups of well-characterized patients to determine the optimum approach for each and to decrease relapse rates. Topical corticosteroids are the mainstay of treatment. All patients with inflammatory polyps should receive topical corticosteroid treatment in the long-term, unless there is a compelling contraindication. Adverse effects of surgery are rare but can be devastating. The major side effects of medical therapy are those of oral corticosteroids, which need to be used carefully. The choice of topical corticosteroid is important because long-term use is necessary; the least absorbed should be used. No cost-benefit analysis has been undertaken in this area, although medical therapy is probably cheaper and involves less work/school absence than sinonasal surgery, even when the latter is performed with an endoscope.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Settipane GA: Nasal polyposis: epidemiology, pathology, immunology and treatment. Am J Rhinol 1987, 1:119–126.
Holmberg K, Karlsson G: Nasal polyps: medical or surgical management? Clin Exp Allergy 1996, 26:323–330.
Stammberger H: Surgical treatment of nasal polyps: past, present and future. Allergy 1999, 54(suppl 53):7–11. An excellent review of the change in surgical approach that has occurred over the past few decades.
Schubert MS: Medical treatment of allergic fungal sinusitis. Ann Allergy Asthma Immunol 2000, 85:90–97. A good review of the upper respiratory tract in patients with cystic fibrosis; essential reading for chest physicians.
Gyssin C, Alothman GA, Papsin BC: Sinonasal disease in cystic fibrosis: clinical characteristics, diagnosis and management. Pediatr Pulmonol 2000, 30:481–489. Another good review of the upper respiratory tract in patients with cystic fibrosis; essential reading for chest physicians.
Watelet JB, Van Cauwenberge P, Bachert C: Rhinological aspects of cystic fibrosis. Monaldi Arch Chest Dis 2000, 55:475–477. Another good review of the rhinologic aspects of cystic fibrosis; essential reading for chest physicians.
Albritton FD, Kingdom TT: Endoscopic sinus surgery in patients with cystic fibrosis: a complication. Am J Rhinol 2000, 14:379–385.
Badia L, Lund VJ: Topical corticosteroids in nasal polyposis. Drugs 2001, 61:573–578. A nice overview of the role and effects of topical corticosteroid in nasal polyposis.
Passali D, Mezzedimi C, Passali GC, Bellussi L: Efficacy of inhalation form of furosemide to prevent postsurgical rhinosinusal polyposis. ORL J Otorhinolaryngol Relat Spec 2000, 62:307–310.
Lascaratos JG, Segas JV, Assimakopoulos DA: Treatment of nasal polyposis in Byzantine times. Ann Otol Rhinol Laryngol 2000, 109:871–876.
Mackay IS, Lund VJ: Imaging and staging. In Nasal Polyps: An Inflammatory Disease and Its Treatment. Edited by Mygind N, Lildholdt T. Copenhagen: Munksgaard; 1997:137–144.
Kordek P, Dowalski ML, Studniarek M, et al.: CT staging of chronic hyperplastic rhinosinusitis. Przeglad Lek 2000, 57:150–153.
Mygind N, Lildholdt T: Nasal polyps treatment: medical management. Allergy Asthma Proc 1996, 17:275–283.
Holmstrom M: Clinical performance of fluticasone propionate nasal drops. Allergy 1999, 54:21–25. Detailed explanation of the formation and role of cystonile leukotrienes in asthma.
Scadding GK: Safety of topical intranasal corticosteroids [editorial]. In Current Contents: ENT 2002. London, UK: RSM Publishing; In press. There is wide variation in the absorption of different topical corticosteroids. Special care needs to be taken with children and with patients who are receiving steroid therapy at more than one site.
Bisgaard H: Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonist in asthma. Allergy 2001, 56:7–11. The benefits described in this paper apply to some patients with nasal polyposis; however, there are no criteria to distinguish responders from nonresponders.
Ragab S, Parikh A, Darby YC, Scadding GK: An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy 2001, 31:1385–1391.
Ulualp SO, Sterman BM, Toohill RJ: Anti-leukotriene therapy for the relief of sinus symptoms in aspirin triad disease. Ear Nose Throat J 1999, 78:604–616.
Parnes SM, Chuma AV: Acute effects of anti-leukotrienes in sinonasal polyposis and sinusitis. Ear Nose Throat J 2000, 79:18–25.
Barchet C, van Cauwenberge PB, Passalacqua G, et al.: EAACI consensus statement on the treatment of allergic rhinitis. Allergy 2000, 55:116–134. A good review of the anti-inflammatory action of erythromycin and its derivatives in the treatment of chronic sinusitis and nasal polyps. There is in vitro evidence that macrolides reduce the virulence and tissue damage caused by chronic bacterial colonization and may be effective when steroids fail.
Cervin A: The anti-inflammatory effect of erythromycin a nd its derivatives, with special reference to nasal polyposis and chronic sinusitis. Acta Otolaryngol 2001, 121:83–92.
Nucera E, Schiavino D, Milani A, et al.: Effects of lysineacetylsalicylate (LAS) treatment in nasal polyposis: two controlled long-term prospective follow up studies. Thorax 2000, 55:S75-S78. Long-term treatment with lysine aspirin appears to reduce relapse rates and the need for corticosteroids.
Ponicau JU, Sherris DA, Kern EB, et al.: The diagnosis and incidence of allergic fungal sinusitis. Mayo Clinic Proc 1999, 74:877–884. The close association between activated eosinophils and fungi in nasal mucus suggest that the fungi are the primary cause of rhinosinusitis in most patients. Other workers dispute this. Double blind, placebo-controlled studies of topical and oral antifungal therapy are needed.
Patriarca G, Bellioni P, Nucera E, et al.: Intranasal treatment with lysine acetylsalicylate in patients with nasal polyposis. Ann Allergy 1999, 82:588–592.
Stevenson DD, Hankammer MA, Mathison DA, et al.: Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 1996, 98:751–758.
Scadding GK, Hassab M, Darby Y, et al.: Intranasal lysine aspirin in recurrent nasal polyposis. Clin Otol 1995, 20:561–563.
Bruzzese N, Sica G, Iacopino F, et al.: Growth inhibition of fibroblasts from nasal polyps and norm skin by lysine acetylsalicylate. Allergy 1998, 53:431–434.
Kowalski ML: Rhinosinusitis and nasal polyposis in aspirin sensitive and aspirin tolerant patients: Are they different? Thorax 2000, 55(suppl 2):S84-S86. A detailed investigation into the similarities and differences between aspirin-sensitive and aspirin-tolerant patients with rhinosinusitis.
Amayasu H, Nakabayashi M, Akahori K, et al.: Cromolyn sodium suppresses eosinophilic inflammation in patients with aspirin-intolerance. Ann Allergy Asthma Immunol 2001, 87:146–150.
Orlandi RR, Kennedy DW: Surgical management of rhinosinusitis. Am J Med Sci 1998, 316:29–38.
Varga EM, Jacobson MR, Till SJ, et al.: Inflammatory cells populations and cytokine mRNA expression in the nasal mucosa in aspirin-sensitive rhinitis. Eur Respir J 1999, 14:610–705. Rhinitis in aspirin-sensitive patients is associated with an intense eosinophilia present in inferior turbinates and polyps, together with elevated expression of interleukin-5.
Drake-Lee AB: Medical treatment of nasal polyps. Rhinology 1994, 32:1–4.
Zhang BQ: Comparison of results of laser and routine surgery therapy in treatment of nasal polyps. Chin Med J (Engl) 1993, 106:707–708.
Marple BF: Allergic fungal rhinosinusitis: current theories and management strategies. Laryngoscope 2001, 111:1006–1019. A detailed review of allergic fungal sinusitis.
Friedman WH, Katsantonis GP, Slavin RG, et al.: Spenoidethmiodectomy: its role in the asthmatic patient. Otolaryngol Head Neck Surg 1982, 90:171–177.
Friedman WH, Katasantonis GP: Intranasal and transantral ethmoidectomy: a 20-year experience. Laryngoscope 1990, 100:343–348.
Jantti-Alanko S, Holopainen E, Malmberg H: Recurrence of nasal polyps after surgical treatment. Rhinology Suppl 1989, 8:45–49.
Jankowski R, Goetz R, Moneret Vautrin DA, et al.: Insufficiency of ethmoidectomy in the treatment of nasal polyposis. Ann Otolaryngol Chir Cervicofac 1991, 108:298–306.
Ohtori N, Fukami M, Yangagi K, et al.: Improvement of olfactory disturbance by endoscopic surgery for chronic sinusitis. Nippon Jibiinkoka Gakkai Kaiho 1995, 98:642–649.
Lildholdt T, Rundcrantz H, Bende M, Larsen K: Glucocorticoid treatment for nasal polyps: the use of topical powder, intramuscular betamethasone and surgical treatment. Arch Otolaryngol Head Neck Surg 1997, 123:595–600. The first randomized, double-blind study of budesonide, followed by surgery or injected sustained-release betamethasone in patients who failed the initial therapy. Patients with nasal polyps did well with medical treatment, with surgery required in few patients.
Lildholdt T: Surgical versus medical treatment of nasal polyps. Rhinol Suppl 1989,8:31–33.
Blomqvist EH, Lundblad L, Anggard A, Haraldsson PO, Stjarne P: A randomized-controlled study evaluating medical treatment versus surgical treatment in addition to medical treatment of nasal polyposis. J Allergy Clin Immunol 2001, 107:224–228. One of the few controlled prospective studies of medical versus combined surgical and medical treatment of nasal polyposis measuring olfaction, polyp score, and symptoms. Medical treatment seems to be sufficient to treat most symptoms. No benefit is gained from surgical treatment when hyposmia is the primary symptom. If nasal obstruction is the main problem after steroid treatment, surgical treatment is indicated. Selection of the patients who will benefit from surgery should be based on the patient’s symptoms and not on the examiner’s polyp score.
Sharp HR, Crutchfield L, Rowe-Jones JM, Mitchell DB: Major complications and consent prior to endoscopic sinus surgery. Clin Otolaryngol 2001, 26:33–38. Compulsory reading for all who undertake endoscopic sinus surgery.
Findley CA, MacDonald JF, Wallace AM, et al.: Lesson of the week: childhood Cushing’s syndrome induced by betamethasone oral drops and repeat prescriptions. BMJ 1998, 317(7160):739–740.
Homer JJ, Gazis TG: Cushing’s syndrome induced by betamethasone nose drops. BMJ 1999, 318(7194):1355.
Stoloff S, Stempel DA: Churg-Strauss syndrome: Is there an association with leukotriene modifiers? Chest 2000, 118:515–516.
Phillips PP, Gustafson RO, Facer GW: The clinical behavior of inverting papilloma of the nose and paranasal sinuses: report of 112 cases and review of the literature. Laryngoscope 1990, 100:463–469.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scadding, G.K. Comparison of medical and surgical treatment of nasal polyposis. Curr Allergy Asthma Rep 2, 494–499 (2002). https://doi.org/10.1007/s11882-002-0090-2
Issue Date:
DOI: https://doi.org/10.1007/s11882-002-0090-2